SCHEMBL19084539

SCHEMBL19084539

Cc1nn2c(=O)cc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1-c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 5/20 0.52
BTK Q06187 1/20 0.44
CHEK2 O96017 2/20 0.44
MAPT P10636 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 1/20 0.42
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CCR6 P51684 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084536 0.91 PSD (0.48) PSDMAPTMEN1KMT2ALMNA
SCHEMBL19084553 0.89 MAPT (0.54) PSDMAPTMEN1KMT2ALMNA
SCHEMBL19084552 0.85 PSD (0.53) PSDMAPTMEN1KMT2ALMNA
SCHEMBL13516359 0.85 PSD (0.48) PSDMAPTMEN1KMT2ALMNA
SCHEMBL19084664 0.83 PSD (0.51) PSDMAPTMEN1KMT2ALMNA
SCHEMBL1614499 0.83 NPC1 (0.50) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL19084608 0.83 PSD (0.48) PSDMAPTMEN1KMT2ALMNA
SCHEMBL1614079 0.81 MAPT (0.51) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL13516076 0.81 MAPT (0.51) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL1614504 0.81 ADORA2A (0.45) MAPTMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885BTK 3679/4885CHEK2 2704/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885BTK 3679/4885CHEK2 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.